Lilly, Chicago Bears' Cutler throw touchdowns for diabetes

Share this article:
Lilly, Chicago Bears' Cutler throw touchdowns for diabetes
Lilly, Chicago Bears' Cutler throw touchdowns for diabetes
Lilly extended its partnership with Chicago Bears quarterback Jay Cutler through a program that will provide $1,000 to the American Diabetes Association (ADA) for every touchdown pass Cutler completes this season.

Funds raised through the Touchdowns for Diabetes program will help send children with diabetes to ADA's summer camps. Tuition for a week at camp costs approximately $1,000 per child, according to a statement. For every completed pass that isn't a touchdown, Lilly will donate $100.

Scott MacGregor, senior communications associate at Lilly said the company would raise awareness for the program “through various means, including on the Bears Radio Network,” but declined to name any of the agencies involved.

The program's website will add video content in the coming weeks featuring Cutler talking about his own experiences with type 1 diabetes, according to MacGregor. Cutler has worked with Lilly, the ADA and the Juvenile Diabetes Research Foundation in the past, visiting children's hospitals and speaking with kids about the disease. MacGregor said those activities will continue during the off-season.

Cutler played for the Denver Broncos when he became an ambassador for Lilly's diabetes campaign last February, and was traded to the Bears in April.

Lilly diabetes products include Byetta, Humulin, Humalog and Glucagon.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...